BeiGene Appoints Dr. Jinyou Zhang as Senior Vice President, Head of Bioprocess Development and Manufacturing
September 25, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Sept. 25, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Announces the Addition of Dr. Jedd D. Wolchok to Scientific Advisory Board
September 11, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Sept. 11, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Signs Agreement With BioBAY for Its First cGMP Manufacturing Facility for Commercial Use in Suzhou, China
August 20, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Aug. 20, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Announces Appointment of Dr. Howard Liang as Chief Financial and Strategy Officer
August 12, 2015 08:00 ET
|
BeiGene Ltd.
BEIJING, Aug. 12, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-283 for Solid Tumor Cancers
August 03, 2015 11:16 ET
|
BeiGene Ltd.
BEIJING, Aug. 3, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., an innovative oncology company focusing on developing targeted and immuno-oncology therapeutics, today announced that it has received Clinical...
BeiGene Doses First Patient in Phase Ib Study of BGB-283, a Novel Second Generation B-RAF Inhibitor
July 14, 2015 09:56 ET
|
BeiGene Ltd.
- BGB-283 Phase Ia data demonstrates activity against K-RAS and N-RAS mutations not currently targeted by first generation B-RAF inhibitors -
BEIJING, July 14, 2015 (GLOBE NEWSWIRE) -- BeiGene,...
BeiGene Announces IND Approval for BGB-3111, a Bruton Tyrosine Kinase Inhibitor
June 19, 2015 11:51 ET
|
BeiGene Ltd.
BEIJING, June 19, 2015 (GLOBE NEWSWIRE) -- BeiGene Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced that the United States Food and...
BeiGene Enrolls First Patient in Phase I Study of BGB-A317, A Humanized Anti-PD-1 Monoclonal Antibody
June 05, 2015 14:50 ET
|
BeiGene Ltd.
– PD-1 monoclonal antibody will be tested in first-in-human Phase I dose escalation and expansion cohorts in advanced malignancies to establish single-agent properties and preliminary...